Discover your hidden talent with BI Open – the new platform for data science enthusiasts Discover your hidden talent with BI Open – the new platform for data science enthusiasts Discover your hidden talent with BI Open – the new platform for data science enthusiasts. For more talent insights, visit our Careers Page.
Clinical-phase2-trials-NASH-and-obesity Clinical-phase2-trials-NASH-and-obesity Boehringer Ingelheim and Zealand Pharma announced Phase 2 trials of the GLP-1/glucagon dual agonist BI 456906 for adults living with obesity or NASH.
Arti-cell Forte stem cell-based veterinary product Arti-cell Forte stem cell-based veterinary product Boehringer Ingelheim launches the first-ever registered stem cell-based veterinary medicine
Groundbeaking of vaccine production center in France Groundbeaking of vaccine production center in France Boehringer Ingelheim breaks ground on its strategic vaccine production center for veterinary public health
Boehringer Ingelheim and Fraunhofer partnership Boehringer Ingelheim and Fraunhofer partnership Boehringer Ingelheim and Fraunhofer IME launch collaboration which aims to develop sustainable animal health products
Emmanuelle leads a team of scientists Emmanuelle leads a team of scientists Want to work for a company that allows you to grow your career? Emmanuelle talks about her job journey at Boehringer Ingelheim.
BI X colleague about working with purpose BI X colleague about working with purpose Ding works on an app that gives patients remote access to stroke rehabilitation via their mobile phones and tablets
BI 764532: DLL3/CD3 T-cell engager BI 764532: DLL3/CD3 T-cell engager BI 764532: DLL3/CD3 T-cell engager
biolabs-heidelberg biolabs-heidelberg Boehringer Ingelheim supports the launch of BioLabs first European Location in Heidelberg.
BI 764532: DLL3/CD3 T-cell engager | ep-NEC BI 764532: DLL3/CD3 T-cell engager | ep-NEC BI 764532: DLL3/CD3 T-cell engager | ep-NEC
Boehringer Ingelheim appointment to Board Managing Directors Boehringer Ingelheim appointment to Board Managing Directors Boehringer Ingelheim announces appointments to Board of Managing Directors
SPEVIGO (spesolimab) wins 2023 Prix Galien USA Award SPEVIGO (spesolimab) wins 2023 Prix Galien USA Award SPEVIGO® (spesolimab) wins 2023 Prix Galien USA Best Orphan/Rare Diseases Solution Award
Partnership WHO Foundation mental health Partnership WHO Foundation mental health Boehringer Ingelheim and WHO Foundation join forces to promote equitable access to healthcare and increase efforts for suicide prevention
A future without pills – could AI change the way we treat psychiatric diseases? A future without pills – could AI change the way we treat psychiatric diseases? Dr Cornelia Dorner-Ciossek talks about how her work with smartphone tech could transform how we treat mental illness.
cat feline diabetes medication treatment eu approval cat feline diabetes medication treatment eu approval Boehringer Ingelheim receives approval for SENVELGO® in Europe: the first oral liquid medication for diabetic cats
NEJM-IL-36-Phase-1-GPP-data NEJM-IL-36-Phase-1-GPP-data Data published in The New England Journal of Medicine show rapid improvement of symptoms in patients with a rare form of pustular psoriasis
Algorithms to battle heartworm disease Algorithms to battle heartworm disease Partnership with the University of Melbourne uses AI to develop new veterinary solutions for pets
Partnership for new liver disease treatments with Ribo Partnership for new liver disease treatments with Ribo Boehringer Ingelheim partners with Ribo to develop new treatments for people with liver diseases
Interview with Michael Schmelmer Interview with Michael Schmelmer "You can work on initiatives that can improve treatment, provision, and early disease detection"", Michael Schmelmer, Member of the Board of Managing Directors
Over 100 billion birds vaccinated with VAXXITEK Over 100 billion birds vaccinated with VAXXITEK Boehringer Ingelheim celebrates that over 100 billion birds have been vaccinated with VAXXITEK® HVT + IBD in October 2018.